Investigators found the highest risks of short-term hospital and emergency department visits among patients with very low and very high serum potassium levels.
The FDA already approved apple or cranberry juice as alternatives for suspension.
In a study of Medicare beneficiaries who had longer-term care, the risk for hospitalization was 81% higher for patients with vs without hyperkalemia.
Patiromer may be another therapeutic option for patients with both hyperkalemia and hyperphosphatemia.
Ambulance use is more than 20-fold higher among the dialysis than general population, according to investigators.
A mediation analysis was also conducted to analyze the degree to which kidney decline contributes to potassium-related mortality.
New data from DOPPS support previous studies finding higher risk for gastrointestinal injury after use of sodium polystyrene sulfonate.
Nationally standardized treatment algorithms for hyperkalemia should be developed, according to investigators.
Understanding predictors of recurrent hyperkalemia may help health care providers provide a more individualized approach to hyperkalemia management.
In a study of 1117 patients new to hemodialysis, investigators observed an increased 6-month mortality risk associated with low and high predialysis potassium levels.